Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–67 of 67 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TSH Clear all
Completed No phase listed Observational

Improving White Matter Integrity With Thyroid Hormone

NCT04098991
View directory record Official record
Conditions
Hypothyroidism
Interventions
Levothyroxine
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
21 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 23, 2026, 4:24 AM EDT
Recruiting Phase 2 Interventional

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

NCT03841617
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Thyrogen, I-131, I-124, Thyroid hormone withdrawal
Drug · Radiation · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 4:24 AM EDT
Terminated Not applicable Interventional

Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH)

NCT00926978
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Radioactive Iodine 124
Radiation
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 23, 2026, 4:24 AM EDT
Completed Not applicable Interventional Results available

Mechanistic Study of Subclinical Hypothyroidism In the Elderly

NCT02399475
View directory record Official record
Conditions
Subclinical Hypothyroidism
Interventions
Levothyroxine, Liothyronine, Thyrotropin-Releasing Hormone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
70 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 23, 2026, 4:24 AM EDT
Recruiting Phase 4 Interventional

Dosing of LT4 in Older Individuals

NCT06073665
View directory record Official record
Conditions
Hypothyroidism
Interventions
Levothyroxine Sodium
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 23, 2026, 4:24 AM EDT
Completed Phase 2 Interventional

Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter

NCT00454220
View directory record Official record
Conditions
Multinodular Goiter
Interventions
Placebo, MRrhTSH
Other · Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
35 Years to 80 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 23, 2026, 4:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thyroid Function in Late Preterm Infants

NCT00971555
View directory record Official record
Conditions
Transient Hypothyroxinemia
Interventions
Not listed
Lead sponsor
Christiana Care Health Services
Other
Eligibility
Up to 7 Days
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 23, 2026, 4:24 AM EDT
Recruiting Not applicable Interventional

Evaluating a Our Practice Advisory (OPA) to Optimize Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) Test Orders

NCT06993805
View directory record Official record
Conditions
Physician Workflow, Resource Utilization
Interventions
OPA
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 23, 2026, 4:24 AM EDT
Completed No phase listed Observational

Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders

NCT00255671
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Radiation Toxicity
Interventions
Questionnaire
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 23, 2026, 4:24 AM EDT
Completed Phase 1 Interventional

Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123

NCT02278198
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
rhTSH
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Oct 23, 2026, 4:24 AM EDT
Withdrawn Phase 1 Interventional

Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer

NCT02581501
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
GAX - Gemcitabine, Abraxane and Xeloda
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 23, 2026, 4:24 AM EDT
Terminated Phase 3 Interventional Results available

Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer

NCT01843062
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Selumetinib, Placebo, Radioactive Iodine Therapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 23, 2026, 4:24 AM EDT
Terminated No phase listed Observational

Thyroid Hormones in Critically Ill Children

NCT00664079
View directory record Official record
Conditions
Hypotension, Respiratory Failure
Interventions
Blood draws
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Months to 18 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Oct 23, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)

NCT01707225
View directory record Official record
Conditions
Gastrointestinal Bleeding
Interventions
Octreotide LAR Depot
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 23, 2026, 4:24 AM EDT
Terminated Phase 2 Interventional Results available

Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer

NCT00525135
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Valproic Acid
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Oct 23, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy

NCT00388297
View directory record Official record
Conditions
Subclinical Hypothyroidism, Hypothyroxinemia, Pregnancy
Interventions
Levothyroxine, Placebo for Levothyroxine
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
1,203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 23, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants

NCT04124705
View directory record Official record
Conditions
Hypothyroidism, Thyroid Disease, Euthyroid, Thyroid Gland, Thyroid Hormones
Interventions
Armour® Thyroid, Levothyroxine
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Greenbrae, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 23, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131

NCT00085293
View directory record Official record
Conditions
Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer
Interventions
Decitabine, Iodine I 131, Recombinant thyrotropin alfa, Fludeoxyglucose F 18, Positron emission tomography
Drug · Radiation · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
3
States / cities
Aurora, Colorado • Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 23, 2026, 4:24 AM EDT
Completed Phase 3 Interventional

A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

NCT00295763
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Thyrogen (thyrotropin alfa for injection)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
4
States / cities
Aurora, Colorado • Baltimore, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 23, 2026, 4:24 AM EDT